Can you cut your arthritis meds without flaring up? new trial aims to find out
NCT ID NCT07160231
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looks at whether people with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who are doing well on a JAK inhibitor can safely reduce their dose. About 200 participants will either lower their dose or stay on the same dose, guided by disease activity. The goal is to see if the lower dose keeps the disease under control just as well after 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JAK inhibitor dose reduction strategy
What this could lead to
If successful, this could show that many patients can safely lower their JAK inhibitor dose without losing disease control, reducing side effects and costs.
What could go wrong
This is a Phase 4 trial with 200 participants, so results may not apply to everyone. Lowering the dose might lead to disease flares in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Elisabeth-TweeSteden Ziekenhuis Tilburg
NOT_YET_RECRUITINGTilburg, North Brabant, 5022 GC, Netherlands
Contact Email: •••••@•••••
-
Erasmus MC
NOT_YET_RECRUITINGRotterdam, South Holland, 3015 GD, Netherlands
Contact Email: •••••@•••••
-
Isala Zwolle
NOT_YET_RECRUITINGZwolle, Overijssel, 8025 AB, Netherlands
Contact Email: •••••@•••••
-
Maasstad ziekenhuis
NOT_YET_RECRUITINGRotterdam, South Holland, 3079 DZ, Netherlands
Contact Email: •••••@•••••
-
Maastricht UMC+
NOT_YET_RECRUITINGMaastricht, Limburg, 6229 HX, Netherlands
Contact Email: •••••@•••••
-
Medisch Spectrum Twente
NOT_YET_RECRUITINGEnschede, Overijssel, 7512 KZ, Netherlands
Contact Email: •••••@•••••
-
Sint Maartenskliniek Nijmegen
RECRUITINGNijmegen, Gelderland, 6574 NA, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••